Skip to contentN
NovoCure Ltd
N
NVCRNovoCure Ltd Q4 2018 · 10-K
Revenue$69.67M$69.67M+29.8% vs Q4 2017 Net Income-$15.63M-$15.63MN/M vs Q4 2017 EPS Diluted-$0.17-$0.17N/M vs Q4 2017 Gross Profit$46,646,000+22.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
NovoCure Ltd · CIK 1645113 · Engraved from SEC EDGAR
Operating Cash Flowderived$16,814,000N/M Free Cash Flowderived$13,047,000N/M Margins · derivedGross margin66.9%−3.9 pt vs Q4 2017
Operating margin-12.4%−4.0 pt vs Q4 2017
Net margin-22.4%−2.0 pt vs Q4 2017
ended Dec 31, 2018 · filed Feb 28, 2019 · 59 d after period end